Nevro Earnings Reports

Nevro's worldwide revenue for Q4 2024 was $105.5 million, a 9.1% decrease compared to Q4 2023. The company reported a net loss from operations of $51.4 million. Adjusted EBITDA was negative $5.2 million. The company launched HFX iQ™ with HFX AdaptivAI™ and the HFX iQ SCS system in select European countries during the quarter.

Nevro reported a decrease in worldwide revenue by 6.7% to $96.9 million in Q3 2024 compared to Q3 2023. Despite the revenue decline, the company reaffirmed its full-year revenue guidance and raised its adjusted EBITDA guidance. The company is focused on strategic options to accelerate growth and diversify its product portfolio.

Nevro reported a 5.8% increase in worldwide revenue, reaching $101.9 million. The company is raising its adjusted EBITDA guidance to a range of a loss of $5 million to positive $2 million and reaffirming its revenue guidance of $435 million to $445 million for the full-year 2024.

Nevro Corp. reported a 2% increase in worldwide revenue, reaching $116.2 million in Q4 2023. Painful Diabetic Neuropathy (PDN) Indication sales increased by 29% to $22.4 million. The company's net loss from operations was $11.8 million, while adjusted EBITDA was $8.4 million.

Nevro reported a 3% increase in worldwide revenue, reaching $103.9 million in Q3 2023. The growth was driven by a 56% increase in Painful Diabetic Neuropathy (PDN) indication sales, which accounted for approximately $20.8 million. The company updated its full-year 2023 revenue guidance to $417 million to $419 million and expects a positive Non-GAAP Adjusted EBITDA for Q4 2023.

Nevro Corp. reported a 4% increase in worldwide revenue, reaching $108.8 million in Q2 2023, driven by growth in PDN indication sales. The company is taking proactive steps to improve commercial execution and maximize growth opportunities, including optimizing field teams and focusing on patient trial growth and referral physician education.

Nevro Corp. reported a 10% increase in worldwide revenue for Q1 2023, reaching $96.3 million, with Painful Diabetic Neuropathy (PDN) indication sales growing by 160% compared to Q1 2022. The company also initiated the full launch of the HFX iQ™ Spinal Cord Stimulation System in the U.S.

Nevro Corp. reported Q4 2022 worldwide revenue of $113.8 million, an 11% increase as reported and a 12% increase on a constant currency basis compared to Q4 2021. The company's PDN indication sales reached approximately $17.3 million, growing 329% compared to Q4 2021. The company's net loss from operations was $19.4 million and non-GAAP adjusted EBITDA loss was $1.4 million.

Nevro's Q3 2022 worldwide revenue reached $100.5 million, an 8% increase as reported and a 10% increase on a constant currency basis compared to Q3 2021. The company saw encouraging signs of recovery with U.S. trial activity growing by 16% year-over-year and PDN revenue contributing $13.4 million.

Nevro reported a 2% increase in worldwide revenue compared to the prior year, with U.S. revenue increasing by 5%. The company reached a settlement agreement in intellectual property litigations with Boston Scientific and saw positive payer coverage updates for Painful Diabetic Neuropathy (PDN).

Nevro reported a slight decrease in worldwide revenue compared to the previous year, but an increase compared to 2019. The company is optimistic about future growth, particularly with positive payer coverage updates and FDA approval for NSRBP patients.

Nevro reported a decrease in worldwide revenue for Q4 2021, with $102.8 million, a 6% decrease compared to the prior year. The company's net loss from operations was $26.2 million, and non-GAAP adjusted EBITDA was negative $7.5 million. Despite the challenges, Nevro saw progress in its core SCS business and PDN launch initiatives and received FDA approval for 10 kHz High-Frequency Spinal Cord Stimulation Therapy for Non-Surgical Refractory Back Pain.

Nevro reported a 14% decrease in worldwide revenue compared to the prior year, totaling $93.2 million. The company's net loss from operations was $46.4 million, which includes a $20 million patent litigation judgement. However, the company is optimistic about future growth, especially with the recent FDA approval for PDN treatment.

Nevro Corp. reported an 81% increase in worldwide revenue compared to the prior year, reaching $102.3 million. The company also announced FDA approval of its 10 kHz High Frequency Spinal Cord Stimulation Therapy for Painful Diabetic Neuropathy (PDN).

Nevro reported a 1% increase in worldwide revenue for Q1 2021 compared to the previous year, reaching $88.6 million. The company updated its full-year revenue guidance to $440 million to $450 million and non-GAAP adjusted EBITDA guidance to $5 million to $15 million.

Nevro reported a 4% decrease in worldwide revenue for Q4 2020 compared to the prior year, totaling $109.7 million. The company experienced a net loss from operations of $0.9 million, but achieved a non-GAAP adjusted EBITDA of $15.7 million. Nevro anticipates recovery and growth in 2021, with full-year revenue guidance between $430 million and $450 million.

Nevro Corp. reported an 8% increase in worldwide revenue for Q3 2020, reaching $108.5 million compared to $100.2 million in the prior year period. The company is planning to submit its PMA Supplement to the FDA in the fourth quarter of 2020.

Nevro Corp. reported a 40% decrease in worldwide revenue for Q2 2020, totaling $56.4 million, due to COVID-19 restrictions. U.S. revenue decreased by 35% to $51.0 million, while international revenue decreased by 65% on a constant currency basis to $5.4 million. The company experienced a net loss from operations of $35.4 million and an adjusted EBITDA of negative $22.1 million.

Nevro Corp. reported a 6% increase in worldwide revenue for Q1 2020, reaching $87.5 million, despite a negative impact from COVID-19 related cancellations. U.S. revenue increased by 14%, while international revenue decreased by 26%. The company's net loss from operations improved by 45% compared to the prior year period.

Nevro Corp. reported a 6% increase in worldwide revenue for Q4 2019, reaching $114.4 million, with U.S. revenue up 7% to $97.9 million. The company launched Senza Omnia commercially in the U.S. and presented positive data from its Senza-PDN study.